TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α)

被引：2
|
作者：
Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Ctr Leon Berard, Serv Cancerol Med, F-69373 Lyon, France
[6] Pfizer Inc, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4594
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Cella, D.
    Michaelson, M. D.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A283 - A283
  • [22] Phase III randomized trial of sunitinib malate (SU11248) versus interferon- alfa (IFN-A) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC)
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 53 - 54
  • [23] Outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su).
    Kushnir, Igal
    Rosenbaum, Eli
    Sarid, David Leonid
    Sella, Avishay
    Gottfried, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Neiman, Victoria
    Kovel, Svetlana
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Berger, Raanan
    Keizman, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su).
    Kushnir, Igal
    Rosenbaum, Eli
    Sella, Avishay
    Sarid, David
    Gottfried, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Neiman, Victoria
    Kovel, Svetlana
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Berger, Raanan
    Keizman, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [25] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Carducci, Michael Anthony
    Berger, Raanan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [30] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Pili, Roberto
    Bjarnason, Georg A.
    Garcia-del-Muro, Xavier
    Sosman, Jeffrey A.
    Solska, Ewa
    Wilding, George
    Thompson, John A.
    Kim, Sindy T.
    Chen, Isan
    Huang, Xin
    Figlin, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3584 - 3590
12345